Clinical trials
Every registered trial of Retatrutide
43 studies, 2 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Retatrutide has a real but limited body of human research.
- 43 registered studies in total.
- 2 are still enrolling people, so this is active research, not just history.
What kind of research
- 42 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 29,131 people took part in those.
How far along it is
- 14 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 6 have published results in the medical literature that anyone can read.
- The research spans 38 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 43 of 43 trials for Retatrutide.
N1T-MC-MALO
Eli Lilly & Co.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Hudson Biotech
Obesity
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company
Obesity · Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Eli Lilly and Company
Obesity · Overweight
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Eli Lilly and Company
Type 2 Diabetes Mellitus
J1I-MC-GZQF
Eli Lilly & Co.
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Diabetes Mellitus · Insulin Sensitivity
J1I-MC-GZQG
Eli Lilly & Co.
Diabetes Mellitus
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company
Obesity · Overweight · Chronic Low Back Pain (CLBP)
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company
Obesity
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
Eli Lilly and Company
Healthy
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly and Company
Obesity
J1I-MC-GZBP
Eli Lilly & Co.
Obesity
J1I-MC-GZBU
Eli Lilly & Co.
Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Eli Lilly and Company
Diabetes Type 2
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Eli Lilly and Company
Obesity
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company
Type 2 Diabetes
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company
Diabetes Mellitus, Type 2
J1I-MC-GZBJ, -GOA1
Eli Lilly & Co.
Obesity, Overweight, Osteoarthritis, Knee
J1I-MC-GZBN
Eli Lilly & Co.
Osteoarthritis, Knee, Obesity, Overweight
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Eli Lilly and Company
Overweight
J1I-MC-GZBM
Eli Lilly & Co.
Cardiovascular Disease, Obesity
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
Eli Lilly and Company
Healthy
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly and Company
Obesity · Overweight · Osteo Arthritis Knee
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
Overweight or Obesity · CKD · Type 2 Diabetes
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
Eli Lilly and Company
Healthy
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Eli Lilly and Company
Healthy · Hepatic Insufficiency
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company
Type 2 Diabetes · Obesity · Overweight · Obstructive Sleep Apnea
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company
Obesity · Overweight · Osteoarthritis, Knee · Obstructive Sleep Apnea
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company
Obesity · Cardiovascular Diseases
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
Eli Lilly and Company
Healthy
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
Eli Lilly and Company
Healthy · Renal Insufficiency
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
Eli Lilly and Company
Overweight · Obesity
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Eli Lilly and Company
Obesity
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Eli Lilly and Company
Obesity · Overweight
A Study of LY3437943 in Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
Eli Lilly and Company
Healthy
- NCT07629401Available
Pre-approval Expanded Access of Retatrutide (LY3437943)
Eli Lilly and Company
Obesity · Obesity-related Complications
J1I-MC-GZQD
Eli Lilly & Co.
Overweight, Chronic Low Back Pain (CLBP), Obesity
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Retatrutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.